NANOACTIVE LIFT

99% up

Product categories

New Products

Product Details

Product Information

Product name	Nanoactive Lift
INCI Names	Water, Acetyl Dipeptide-1 Cetyl Ester, Phospholipids, Plectranthus barbatus root extract
Molecular Formula	C33H57N5O5
CAS No.	196604-48-5/7732-18-5/123456-35-0
Quality Standard	99% up
Appearance	Colorless to light beige / Odorless
Solubility	100% soluble in water and oil

COA of Nanoactive Lift

Test items	Specifications	Result
Color	Colorless to light beige	Complied
Odor	Odorless	Complied
pH	5.0 - 8.0	6.8
Micorbiological Properties:
Aerobic plate	≤100 CFU/g	21 CFU/g
Yeast & Molds	≤10 CFU/g	1 CFU/g
Escherichia coli presence	Negative	Complied
Salmonella	Negative	Complied

Usage

Function of Nanoactive Lift
Anti-aging focus on eye care products, 73% of the eye care products have claimed to be anti-aging. 62% of eye care products have claimed they can reduce wrinkles and fine lines.

NanoLift is composed by plectranthus barbatus root extract and synthetic peptide acetyl dipeptide-1 cetyl ester combined with nanotechnology, which has fast penetration and efficiency. Significant improvement in wrinkles can be observed immediately after using.

The chemical compositions of plectranthus barbatus is diverse and has been

isolated from roots and overground parts, including terpenoids, flavones, sterols, volatile oils, etc. Nano Lift used the root extract of plectranthus barbatus.

Acetyl dipeptide-1 cetyl ester has very good stimulation effect on the synthesis of elastin. In vitro research, Nano Lift has bounced deposition of elastin fiber and elastin to 94% in the extracellular matrix. Nano Lift acts on each stage of elastic tissue formation. Elastic tissue does not only have elastic proteins, but also made up of a variety of proteins.

Features of Nano Lift

1. Nano Lift has good thermal, pH and shear stability, easy to use.

2. Nano Lift has significantly improved the stability and bioavailability.

3. Nano Lift can greatly enhance the absorption.

4. Nano Lift is 100 % water soluble and 100% oil soluble (amphipathy) with wide range of application.

5. The raw material of Nano Lift meet the FDA GRAS standard

Product Efficacy

1. Instantly lift the facial contour

2. Long-term protection against skin sagging

3. Improve wrinkles around the eyes

4. Repair wrinkles on neck

5. tightness, slimming

The normal operation of the nervous system will not be affected after Nano Lift acts on the synapses. Nano Lift has a quick effect on emoticons.

Nano Lift adjusts dosage according to the effects. It improves wrinkles and facial expressions lines through neuromuscular interactions -Nano Lift won't paralyze muscles. The effect lasts for more than 8 hours. After 8 hours, users can still feel crow's-feet fewer and skin is tighter than before.

Using the cream containing 4% Nano Lift on women aged 54 to 75 with sagging skin for a month, as shown in the picture, the smile lines were significantly reduced.

80% of the test people have stronger skin after using the cream with 4% Nano Lift.The problems of skin flabby, droopy and furrow depth have been improved.

Product use:

Add at 45 ℃

Recommended Quantity: 1-10%. The system should avoid ferrous divalent and trivalent metal ions

Product storage: avoid light preservation under 25 ℃

Hot Tags : nanoactive lift nano lift lift nanoactive products nano active nano active cosmetic

Send A Message

Next : Nanoactive Astaxanthin 472-61-7

Related Products

Nanoactive Soy Isoflavones (ISO) 574-12-9

5% by HPLC

Nanoactive Resveratrol (RES) 501-36-0

5% by HPLC

Nanoactive Astaxanthin 472-61-7

5% up by HPLC

GUAIAZULENE 489-84-9

99.90 % up by HPLC

Boc-(R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoic acid / Sitagliptin intermediate 486460-00-8

98% up by HPLC

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.